Patient-Reported Outcome (PRO) Data in Oncology NDAs Approved by the FDA (2018- 2021): A Review of Criticism and Concerns in Comments from Regulators
07:30am - 03:35pm EDT - April 5, 2024


Abstract: JNCCN23-0658 https://jnccn.org/view/journal...


Author(s):
Tags: Outcomes and Health Services Research

Display Label Action
025 - General Poster Session Download Handout
Comerford E et al_NCCN Poster_Critical Comments PRO_FDA_v1.2_2024_02_29.pdf Download Handout